| Azimilide vs placebo | No demonstrated result suggested Adverse events leading to treatment discontinuation by 130% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| death or hospitalization for cardiac causes | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Atrial fibrillation recurrence | no data | | Cardiac nonarrhythmic death | no data | | Cardiac arrhythmic death | no data | | Vascular noncardiac death | no data | | hospitalization for AF | no data | | hospitalisation for heart failure | no data | | Pro-arrhythmia | 6.04 [0.78 46.90] | p=1.00 | 0 | 1380 | 1 | ASAP, | | All cause death | 1.23 [0.38 4.03] | p=1.00 | 0 | 1380 | 1 | ASAP, | | non cardiovascular death | no data | | Adverse events leading to treatment discontinuation | 2.30 [1.18 4.47] | p=0.04 | 0 | 1380 | 1 | ASAP, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
